The PARP inhibitor, rucaparib enhances the antitumor activity of 177Lu-DOTA-octreotate radionuclide therapy in preclinical models of neuroendocrine tumor

被引：2
|
作者：
Cullinane, Carleen [1 ]
Waldeck, Kelly [1 ]
Eu, Peter [1 ]
Hicks, Rodney J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1800
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cellular dose-response models for [177Lu]Lu-DOTA-Tyr3,octreotate radionuclide therapy compared to external beam radiotherapy
    Tamborino, G.
    De Saint-Hubert, M.
    Struelens, L.
    Konijnenberg, M. W.
    de Jong, M.
    Nonnekens, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S86 - S87
  • [32] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA Octreotate for Somatostatin Receptor-expressing Neuroendocrine Tumors: The First US Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Erion, Jack
    Somone, Jim
    Wolfangel, Robert
    Wolin, Edward M.
    Espenan, Gregory D.
    PANCREAS, 2013, 42 (02) : 373 - 373
  • [33] Receptor radionuclide therapy with [177Lu-DOTA0]-Tyr3-octreotate (177Lu-DOTATATE) in endocrine tumors: preliminary results
    Bodei, L.
    Bartolomei, M.
    Cremonesi, M.
    Rocca, P.
    Ferrari, M.
    Grana, C.
    Chinol, M.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S100 - S100
  • [34] [177Lu-DOTA0, Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy
    de Jong, M
    Breeman, WAP
    Bernard, BF
    Bakker, WH
    Schaar, M
    van Gameren, A
    Bugaj, JE
    Erion, J
    Schmidt, M
    Srinivasan, A
    Krenning, EP
    INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (05) : 628 - 633
  • [35] Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumors of the small intestine
    Sabet, A.
    Dautzenberg, K.
    Haslerud, T.
    Aouf, A.
    Sabet, A.
    Simon, B.
    Mayer, K.
    Biersack, H.
    Ezziddin, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S211 - S211
  • [36] Initial experience with 177Lu Octreotate targeted radionuclide therapy in patients with metastatic neuroendocrine tumour.
    Buxton-Thomas, M. S.
    Dasgupta, D. J.
    Kalogianni, E.
    Sheeter, N.
    Ramage, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S219 - S219
  • [37] Decrease in tumor uptake and serum Chromogranine A predicts the outcome of peptide receptor radionuclide therapy using [177Lu-DOTA0,Tyr3]octreotate in neuroendocrine tumors
    Kam, BLR
    Kwekkeboom, DJ
    Kooij, PPM
    Krenning, EP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S238 - S238
  • [38] 177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow
    Sansovini, M.
    Grassi, I.
    Severi, S.
    Ianniello, A.
    Nicolini, S.
    Celli, M.
    Amadori, E.
    Di Iorio, V.
    Monti, M.
    Scarpi, E.
    Bongiovanni, A.
    Lambertini, A.
    Grana, C.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S156 - S156
  • [39] γ-H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
    Bussink, Johan
    Span, Paul N.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (04) : 501 - 502
  • [40] Cell death induced by ganciclovir or 177Lu-DOTA-octreotate treatment after gene therapy in vitro in rat and human glioma cell lines
    Verwijnen, SM
    Smitt, PAES
    Hoeben, RC
    Krenning, EP
    de Jong, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S235 - S235
12345